Clinical Trial

Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 25, 2024 (before its estimated August 25, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study aims to assess the efficacy and safety of a combination therapy consisting of Anlotinib, TQB2450 (a PD-L1 inhibitor), and Albumin-bound Paclitaxel regimens in patients with advanced gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA) who have failed the previous treatment with Claudin18.2 (CLDN18.2)-related regimens.
Trial Details
NCT Number NCT06222944
Lead Sponsor Peking University
Collaborators: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Gastric Cancer, Adenocarcinoma of Esophagogastric Junction
Enrollment 90 participants
Start Date 2024-02-25
Primary Completion 2025-08-25 (estimated)
Study Completion 2026-08-25 (estimated)
Updated on ClinicalTrials.gov 2024-01-25